Ensysce secures up to $10M R&D funding from Galephar in equity-based development deal

Ensysce Biosciences, Inc.

Galephar commits up to $10 million to support R&D, manufacturing, and testing of PF614 and PF614-MPAR.
Ensysce issues 1% of outstanding shares as restricted stock vesting in thirds based on project milestones.
Development costs compensated with 50% restricted stock and 50% freely tradeable shares at 1.2x actual cost.
15-year term with IP created related to Ensysce's products owned exclusively by Ensysce.
Share price fixed using trailing five-day closing price; no future variable pricing permitted.

item 1.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-004880
form_type: 8-K
ticker: ENSC
cik: 0001716947
company_name: Ensysce Biosciences, Inc.
filed_at: 2025-02-04T23:59:59+00:00
discovered_at: 2026-05-14T18:03:04.570570+00:00
generated_at: 2026-05-27T03:33:33.611178+00:00
sec_items: ["1.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-004880
json_url: https://secwatch.observer/filing/0001493152-25-004880.json
markdown_url: https://secwatch.observer/filing/0001493152-25-004880.md
text_url: https://secwatch.observer/filing/0001493152-25-004880.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315225004880/0001493152-25-004880-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315225004880/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-25-004880

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.